logo-loader
viewBioPorto

BioPorto Diagnostics A/S looks for FDA approval for its kidney diagnostic test

BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen joins Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The Copenhagen, Denmark based in-vitro diagnostics company provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury.

Quick facts: BioPorto

Price: - -

NASDAQ OMX:BIOPOR
Market: NASDAQ OMX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Impact of coronavirus on speciality metals 'about to bite' as China industry...

Commodity strategist and chairman of Critical Metals Plc Christopher Ecclestone gives his view on the impact he's expecting coronavirus to have on China as far as imports and exports. ''The effect so far has been limited but it's about to start to bite because with all of these speciality...

7 hours, 16 minutes ago

2 min read